Trevi Therapeutics Inc (NASDAQ: TRVI) kicked off on November 20, 2023, at the price of $1.41, down -6.47% from the previous trading day. During the day, the shares moved up to $1.41 and dropped to $1.28 before settling in for the closing price of $1.39. Over the past 52 weeks, TRVI has traded in a range of $1.15-$3.50.
While this was happening, its average annual earnings per share was recorded 31.85%. With a float of $41.30 million, this company’s outstanding shares have now reached $59.94 million.
The firm has a total of 25 workers. Let’s measure their productivity.
Trevi Therapeutics Inc (TRVI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Trevi Therapeutics Inc is 35.33%, while institutional ownership is 46.05%. The most recent insider transaction that took place on Oct 11, was worth 1,586. In this transaction Chief Financial Officer of this company sold 785 shares at a rate of $2.02, taking the stock ownership to the 35,901 shares. Before that another transaction happened on Sep 11, when Company’s Chief Financial Officer sold 711 for $2.20, making the entire transaction worth $1,564. This insider now owns 34,394 shares in total.
Trevi Therapeutics Inc (TRVI) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$0.08 earnings per share (EPS), higher than consensus estimate (set at -$0.09) by $0.01. This company achieved a return on equity of -46.82. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.85% per share during the next fiscal year.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Take a look at Trevi Therapeutics Inc’s (TRVI) current performance indicators. Last quarter, stock had a quick ratio of 18.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Analysing the last 5-days average volume posted by the [Trevi Therapeutics Inc, TRVI], we can find that recorded value of 0.4 million was better than the volume posted last year of 0.17 million. As of the previous 9 days, the stock’s Stochastic %D was 52.03%. Additionally, its Average True Range was 0.15.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 11.28%, which indicates a significant decrease from 21.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.33% in the past 14 days, which was higher than the 58.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8569, while its 200-day Moving Average is $2.2262. Now, the first resistance to watch is $1.3800. This is followed by the second major resistance level at $1.4600. The third major resistance level sits at $1.5100. If the price goes on to break the first support level at $1.2500, it is likely to go to the next support level at $1.2000. Should the price break the second support level, the third support level stands at $1.1200.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
The company with the Market Capitalisation of 83.02 million has total of 63,858K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -29,150 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -7,700 K.